About Oculis
Oculis is a publicly listed company based in Pully (Switzerland) founded in 2003 by Einar Stefansson. It operates as an ophthalmic drug design and delivery platforms are developed by Oculis. Oculis has raised $93.21 million across 5 funding rounds from investors including European Union, Tekla Capital Management and BioVeda China Fund. The company has 49 employees. Its chief executive is Riad Sherif. Its website oculis.com draws about 17 thousand monthly visits. Oculis offers products and services including OCS-01, OCS-02, and OCS-05. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified. Its legal entity is OCULIS US INC. Its competitors include Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
Oculis was founded in 2003 in Pully, Switzerland, and operates in the biotechnology sector focused on eye care. Ophthalmic drugs are designed and delivered through a specialized platform. The lead product, OCS-01, is formulated as a non-invasive topical treatment using solubilizing nanoparticle technology. It targets diabetic macular edema, post-surgery cataract inflammation, and dry eye conditions. Key personnel include co-founder Einar Stefansson and CEO Riad Sherif.
- Headquarters Pully, Switzerland
- Employees 49
- Founders Einar Stefansson
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website oculis.com
- Social LinkedIn
- Legal Name Oculis Holding Ag
- Net Profit-$119.16 M (USD)-22.34as on Dec 31, 2025
- EBITDA-$99.13 M (USD)-18.8as on Dec 31, 2025
- Total Equity Funding$93.21M (USD)
in 5 rounds
- InvestorsEuropean Union
& 13 more
- Employee Count49
Products & Services of Oculis
Oculis offers a comprehensive portfolio of products and services, including OCS-01, OCS-02, and OCS-05.
Targets diabetic macular edema with non-invasive eye drops.
Treats dry eye disease by reducing ocular inflammation.
Addresses acute optic neuritis for potential vision protection.
Funding Insights of Oculis
Oculis has successfully raised a total of $93.21M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $93.21M
- Total Rounds 5
- First Round $320,157
(Dec 2017)
- Investors Count 14
All 5 funding rounds of Oculis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | – | Post-IPO | – | – | – |
| May 2021 | $57M | Series C | – | BioVeda China Fund, Hyfinity Investments | |
| Jan 2019 | $15.69M | Series B | – | Tekla Capital Management | |
| Jan 2018 | $20.52M | Series B | – | Bay City Capital, Novartis Venture Fund | |
| Dec 2017 | $320,157 | Grant | – | – |
14 investors in total: 14 institutional.
Investors in Oculis
Oculis has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Tekla Capital Management and BioVeda China Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC firm funding companies in China and the US | – | bvcf.com | Huangpu, China | |
- | – | hyfinityfund.com | - | |
Early-stage venture capital is invested in US and Europe. | – | vipartners.ch | Altendorf, Switzerland | |
Investments are made in real estate, digital media, and tech. | – | willefinance.com | Zurich, Switzerland | |
Stage-agnostic investments in US life-sciences sectors are managed. | – | baycitycapital.com | San Francisco, United States | |
Earlybird is recognized as a venture capital investor focused on early-stage tech companies. | – | earlybird.com | Berlin, Germany | |
Venture capital investments are directed toward startups by the firm. | – | brunnurventures.com | Reykjavik, Iceland | |
Corporate backed venture capital firm investing in life sciences sector | – | nanfunglifesciences.com | San Francisco, United States | |
Investments are made in innovative life science companies globally. | – | nvfund.com | Basel, Switzerland | |
Silfurberg operates a chain of hotels offering quality lodging and guest services. | 2012 | silfurberg.com | Egilsstadir, Iceland |
Investor details for Oculis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Oculis
43 people are tracked at Oculis (21 in leadership, 18 in board & advisors, 4 in team); the tracked headcount is 49.
| Name | Role | Group |
|---|---|---|
Einar Stefansson | Co-Founder | Leadership |
Riad Sherif | CEO | Leadership |
Sylvia Cheung | Chief Financial Officer | Leadership |
Páll Ragnar Jóhannesson | Chief Strategy Officer | Leadership |
Molly O'Leary | Director, Technical Accounting And SEC Reporting | Leadership |
Petra Egger | Executive Legal Director | Leadership |
Will Caron | Director Of Financial Planning And Analysis | Leadership |
David Jacobs | Chief Development Officer | Leadership |
Gudrun Bachmann | Chief Technology Officer | Leadership |
Sunna Jóhannsdóttir | Director of Formulation Development / Formulation scientist III | Leadership |
Eric Wu | Director of Financial Planning and Analysis | Leadership |
Maria Saiz Garcia | Vice President Finance | Leadership |
Luke Zack | Senior Director, Global Regulatory Affairs Strategy | Leadership |
Louie Anne Gauthier | VP of Strategic Marketing and& Business Development & Licensing | Leadership |
Rebecca Weil | Chief Commercial Officer | Leadership |
Kate Allman | Vice President, Clinical Operations | Leadership |
Sharon Klier | Svp, Chief Development Officer | Leadership |
Jonathan Barber | Vice President, Head Of Global Regulatory Affairs | Leadership |
Rebecca W. | Chief Commercial Officer (cco) | Leadership |
Maxime Petetot | Senior Director CMC | Leadership |
23 more people are available in the full profile.
Complete people profiles for Oculis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Oculis
Oculis is a publicly listed company on the NASDAQ with ticker symbol OCS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date02 Jun 2023
- Listed onFRA: CR5
- Listed entityOculis Holding AG
- Exchange sectorHealth technology
- ISINCH1242303498
- Share price$7.62 (-3.3% on the day) · 2026-10-13
- Market capitalisation$470.4M
- EPS (diluted, trailing year)$-1.76
- Volume (last session)320,225
Financials of Oculis
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$119.2M | -$99.1M |
| 2024 | – | -$97.4M | -$83.4M |
| 2023 | – | -$98.8M | -$51.7M |
| 2022 | – | -$40.5M | -$34.5M |
| 2021 | – | $1.5M | -$1.1M |
Detailed financial statements for Oculis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Oculis
4 dated milestones of Oculis across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Oculis is founded.
- Funding First funding round of $320K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Competitors of Oculis
Oculis has 9 listed competitors in our database, 7 of them funded. They include Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. | |
| nicox.com | 1996 | Valbonne, France | $271.01M | – | Nitric oxide-based therapeutics for glaucoma and eye conditions are developed. | |
| gyroscope.cc | 2016 | San Francisco, United States | – | – | Mobile SDK developed for app engagement and monetization strategies. | |
| meiragtx.com | 2015 | New York, United States | – | 358 | Gene therapies for ocular and neurodegenerative diseases are developed. | |
| perceivebio.com | 2021 | San Francisco, United States | $78M | – | Developer of therapeutics to treat diabetes and eye diseases | |
| alimerasciences.com | 2003 | Alpharetta, United States | $66.8M | 79 | Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | |
| gensight-biologics.com | 2011 | Paris, France | $76.63M | – | Viral vector-based gene therapies for retinal diseases are developed. |
Detailed competitors of Oculis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Oculis
The website of Oculis (oculis.com) receives about 17.2K visits a month.
- Monthly visits17.2K
▲ 85% vs previous month
Top companies in Ophthalmology
10 companies that operate in the same segment as Oculis (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oculis
Complete news archive for Oculis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oculis
Oculis was founded in 2003 and raised its 1st funding round 14 years after it was founded.
Oculis is headquartered in Pully, Switzerland. It is registered at Pully, Vaud, Switzerland.
Riad Sherif is the current CEO of Oculis.
Oculis is a funded company, having raised a total of $93.21M across 5 funding rounds to date. The company's 1st funding round was a Grant of $320.16K, raised on Dec 2017.
Oculis has 49 employees.
Oculis was founded in 2003 in Pully, Switzerland, and operates in the biotechnology sector focused on eye care. Ophthalmic drugs are designed and delivered through a specialized platform. The lead product, OCS-01, is formulated as a non-invasive topical treatment using solubilizing nanoparticle technology. It targets diabetic macular edema, post-surgery cataract inflammation, and dry eye conditions. Key personnel include co-founder Einar Stefansson and CEO Riad Sherif.
Oculis's top competitors include Annexon, Alimera Sciences and MeiraGTx.
Oculis offers OCS-01, OCS-02, and OCS-05.
Yes, Oculis is publicly traded on NASDAQ under the ticker symbol OCS.
Oculis has 14 investors. Key investors include European Union, Tekla Capital Management, BioVeda China Fund, Hyfinity Investments, and VIP Partners.
Oculis operates through Oculis Us Inc.